155 related articles for article (PubMed ID: 38621678)
1. CNS Aspergillosis and Cryptococcosis with Cytomegalovirus Pneumonia in a Patient with Chronic Lymphocytic Leukemia Treated with Acalabrutinib.
Fallin T; Thacker E; Sahra S; Siegrist EA; White BP; Summers K; Shibib D; Sassine J
J Pharm Pract; 2024 Apr; ():8971900241247660. PubMed ID: 38621678
[TBL] [Abstract][Full Text] [Related]
2. Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor.
Alkharabsheh O; Alsayed A; Morlote DM; Mehta A
Curr Oncol; 2021 Feb; 28(1):837-841. PubMed ID: 33567487
[TBL] [Abstract][Full Text] [Related]
3. Invasive Aspergillosis with impaired neutrophil responses against Aspergillus fumigatus in patients treated with Acalabrutinib-findings from three cases.
Blaize M; Thizy G; Boissonnas A; Portalier A; Lanternier F; de La Porte des Vaux C; Suarez F; Bougnoux ME; Guitard J; Jabet A; Stocker N; Aoudjhane A; Roos-Weil D; Fekkar A
Int J Infect Dis; 2024 May; 142():107000. PubMed ID: 38461932
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Thompson MC; Mato AR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
[TBL] [Abstract][Full Text] [Related]
5. Practical management of chronic lymphocytic leukemia with acalabrutinib.
Kuss B; Nagarajan C; Hsieh WS; Cheah CY
Leuk Lymphoma; 2022 Dec; 63(12):2785-2794. PubMed ID: 35852229
[TBL] [Abstract][Full Text] [Related]
6. The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
Catania G; Tavarozzi R; Pini GM; Borra T; Gandolfo C; Zacchi G; Pietrasanta D; Monaco F; Zanni M; Lettieri M; Rivela P; Zallio F; Ladetto M
J Basic Clin Physiol Pharmacol; 2023 May; 34(3):401-404. PubMed ID: 37040263
[TBL] [Abstract][Full Text] [Related]
7. Invasive Fungal Infection Complicating Treatment With Ibrutinib.
Rajapakse P; Gupta M; Hall R
Cureus; 2021 Jun; 13(6):e16009. PubMed ID: 34336499
[TBL] [Abstract][Full Text] [Related]
8. Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Hatashima A; Karami M; Shadman M
Expert Opin Pharmacother; 2022 Sep; 23(13):1545-1557. PubMed ID: 35973973
[TBL] [Abstract][Full Text] [Related]
9. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
Miao Y; Xu W; Li J
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396
[TBL] [Abstract][Full Text] [Related]
10. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.
Jacobs R; Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Levy MY
Future Oncol; 2024 Jan; 20(1):39-53. PubMed ID: 37476983
[TBL] [Abstract][Full Text] [Related]
11. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia.
Arthurs B; Wunderle K; Hsu M; Kim S
Respir Med Case Rep; 2017; 21():27-29. PubMed ID: 28377877
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Brochard J; Morio F; Mahe J; Le Pape P; Guimard T; Mahe B; Leterrier M; Morrier M; Raffi F; Boutoille D
Med Mal Infect; 2020 Nov; 50(8):742-745. PubMed ID: 32777360
[TBL] [Abstract][Full Text] [Related]
13. Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data.
Isaac K; Mato AR
Cancer Manag Res; 2020; 12():2079-2085. PubMed ID: 32256115
[TBL] [Abstract][Full Text] [Related]
14. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Byrd JC; Hillmen P; Ghia P; Kater AP; Chanan-Khan A; Furman RR; O'Brien S; Yenerel MN; Illés A; Kay N; Garcia-Marco JA; Mato A; Pinilla-Ibarz J; Seymour JF; Lepretre S; Stilgenbauer S; Robak T; Rothbaum W; Izumi R; Hamdy A; Patel P; Higgins K; Sohoni S; Jurczak W
J Clin Oncol; 2021 Nov; 39(31):3441-3452. PubMed ID: 34310172
[TBL] [Abstract][Full Text] [Related]
15. Targeting Bruton's Tyrosine Kinase in CLL.
Ahn IE; Brown JR
Front Immunol; 2021; 12():687458. PubMed ID: 34248972
[TBL] [Abstract][Full Text] [Related]
16. BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.
Fiorcari S; Maffei R; Vallerini D; Scarfò L; Barozzi P; Maccaferri M; Potenza L; Ghia P; Luppi M; Marasca R
Front Immunol; 2020; 11():2158. PubMed ID: 32983178
[TBL] [Abstract][Full Text] [Related]
17. Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
Egyed M; Lueff S; Borbely J; Illes A
Future Oncol; 2022 Mar; 18(7):755-769. PubMed ID: 35139644
[TBL] [Abstract][Full Text] [Related]
18. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
19. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Byrd JC; Harrington B; O'Brien S; Jones JA; Schuh A; Devereux S; Chaves J; Wierda WG; Awan FT; Brown JR; Hillmen P; Stephens DM; Ghia P; Barrientos JC; Pagel JM; Woyach J; Johnson D; Huang J; Wang X; Kaptein A; Lannutti BJ; Covey T; Fardis M; McGreivy J; Hamdy A; Rothbaum W; Izumi R; Diacovo TG; Johnson AJ; Furman RR
N Engl J Med; 2016 Jan; 374(4):323-32. PubMed ID: 26641137
[TBL] [Abstract][Full Text] [Related]
20. Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia.
Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Jacobs R
Patient Prefer Adherence; 2023; 17():2073-2084. PubMed ID: 37641660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
